Clinical Trial Results, New Products, Employee Grants, Pricing of Offering - Research Report on GSK, Intuitive, IDEXX, Sanofi,

 Clinical Trial Results, New Products, Employee Grants, Pricing of Offering -
  Research Report on GSK, Intuitive, IDEXX, Sanofi, and Foundation Medicine

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 19, 2013

NEW YORK, November 19, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting
GlaxoSmithKline plc (NYSE: GSK), Intuitive Surgical, Inc. (NASDAQ: ISRG),
IDEXX Laboratories, Inc. (NASDAQ: IDXX), Sanofi SA (NYSE: SNY), and Foundation
Medicine, Inc. (NASDAQ: FMI). Today's readers may access these reports free of
charge - including full price targets, industry analysis and analyst ratings -
via the links below.

GlaxoSmithKline plc Research Report

On November 12, 2013, GlaxoSmithKline plc (GSK) announced top-line results
from its Phase III STABILITY trial, which evaluated the efficacy of its
investigational Lp-PLA2 inhibitor darapladib in adults with chronic coronary
heart disease (CHD). According to GSK, the study did not meet the primary
endpoint measure, which was time to first occurrence of any major adverse
cardiovascular event from the composite of myocardial infarction (heart
attack), stroke, and cardiovascular death (relative risk reduction of 6%;
p=0.199), however there were greater reductions (nominal p<=0.05) in some of
the pre-defined secondary endpoints that require further analysis. The Company
informed that in the trial the overall safety profile did not demonstrate
major imbalance in serious adverse events between the active and placebo
groups. GSK stated that further analysis of the data is ongoing and the
Company will submit the full results of the STABILITY study for presentation
at a scientific meeting in to be held in 2014. According to GSK, darapladib is
not approved for use anywhere in the world. The Full Research Report on
GlaxoSmithKline plc - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/2a35_GSK

--

Intuitive Surgical, Inc. Research Report

On November 8, 2013, Intuitive Surgical, Inc. (Intuitive) reported that that
the equity awards, which were approved by the Compensation Committee of the
Board of Directors, were granted to 22 new employees. According to the
Company, the awards were granted under the Company's 2009 Commencement
Incentive Plan, pursuant to NASDAQ Marketplace Rule 5635(c) (4). The Company
stated that the awards granted the 22 employees, options to purchase an
aggregate of 6,605 shares of Intuitive's common stock at an exercise price of
$379.58 per share. Intuitive stated that the options vest over four years will
expire in 10 years, assuming continued employment. The Full Research Report on
Intuitive Surgical, Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/5f98_ISRG

--

IDEXX Laboratories, Inc. Research Report

On November 14, 2013, IDEXX Laboratories, Inc. (IDEXX) reported that it has
introduced the SNAP Pro Mobile Device, and has started taking pre-orders for
the product in North America while shipment of the same is anticipated by late
Q1 2014. According to the Company, SNAP Pro Mobile Device is the latest
innovation in rapid point-of-care diagnostic testing. IDEXX stated that the
core feature of the stated device includes - fast and easy to use, improves
staff efficiency and saves practices money and Populates VetConnect PLUS with
additional diagnostic results. Dana Belisle, Vice President and General
Manager of IDEXX Rapid Assay said, "The immediate, accurate results provided
by SNAP tests are an essential part of everyday diagnostic protocols for tens
of thousands of practices worldwide. Adding the SNAP Pro Mobile Device to
established protocols significantly improves practice efficiency by automating
the entire SNAP test process." The Full Research Report on IDEXX Laboratories,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/bf62_IDXX

--

Sanofi SA Research Report

On November 7, 2013, Sanofi SA (Sanofi) announced that it has priced its
offering of €1 billion of notes, due by 2023, bearing interest at an annual
rate of 2.50%. The Company informed that the issue is drawn under the
Company's Euro Medium Term Note Programme and it plans to use the proceeds of
the offering for general corporate purposes, including payment of existing
borrowings. The Full Research Report on Sanofi SA - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/29ea_SNY

--

Foundation Medicine, Inc. Research Report

On November 8, 2013, Foundation Medicine, Inc. (Foundation Medicine) announced
that it will present new clinical data featuring its second clinical product,
a fully informative genomic profile for hematologic malignancies, which was
developed in collaboration with Memorial Sloan-Kettering Cancer Center, at the
55th American Society of Hematology (ASH) Annual Meeting and Exposition.
Foundation Medicine stated that the event is scheduled to take place from
December 7, 2013 through December 10, 2013 in New Orleans. Vincent Miller,
M.D., Chief Medical Officer of Foundation Medicine said, "We are making
progress toward the introduction of our second clinical product, FoundationOne
Heme, by early 2014 and look forward to sharing initial data with the
hematology community at this year's ASH meeting. We are building on our
comprehensive next-generation sequencing platform to offer a fully informative
genomic profile with clinically actionable information for oncologists and
patients with hematologic malignancies. We believe these findings will advance
patient care for blood based cancers." The Full Research Report on Foundation
Medicine, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/d9a0_FMI

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)